Enbezotinib Explained

Drug Name:	Enbezotinib
C:	21
H:	21
F:	1
N:	6
O:	3
Iupac Name:	(1^5aR,1^8aS,5S)-3⁵-fluoro-5-methyl-1^5a,1⁷,1⁸,1^8a-tetrahydro-1⁶H-4-oxa-7-aza-1(5,3)-cyclopenta[b]pyrazolo[1',5':1,2]pyrimido[4,5-e][1,4]oxazina-3(3,2)-pyridinacyclooctaphan-8-one
Cas Number:	2359649-81-1
Cas Supplemental:	2359650-19-2
Pubchem:	146662764
Smiles:	C[C@H]1CNC(=O)C2=C3N=C4C(=CN3N=C2)O[C@H]5CCC[C@H]5N4CC6=C(O1)N=CC(=C6)F
Stdinchi:	1S/C21H21FN6O3/c1-11-6-23-20(29)14-8-25-28-10-17-19(26-18(14)28)27(15-3-2-4-16(15)31-17)9-12-5-13(22)7-24-21(12)30-11/h5,7-8,10-11,15-16H,2-4,6,9H2,1H3,(H,23,29)/t11-,15+,16-/m0/s1
Stdinchikey:	BYYQDEOVMILBQT-XZJROXQQSA-N

Enbezotinib (TPX-0046) is an experimental anticancer medication which acts as a RET inhibitor, as well as an inhibitor of SRC kinase.^[1] ^[2]

Notes and References

Repetto M, Crimini E, Ascione L, Boscolo Bielo L, Belli C, Curigliano G . The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 . Investigational New Drugs . 40 . 5 . 1133–1136 . October 2022 . 35612671 . 10.1007/s10637-022-01259-x . 246502280 .
Gou Q, Gan X, Li L, Gou Q, Zhang T . Precious Gene: The Application of RET-Altered Inhibitors . Molecules (Basel, Switzerland) . 27 . 24 . December 2022 . 8839 . 36557971 . 9784389 . 10.3390/molecules27248839 . free .